What a Physician-Supervised Peptide Program Involves, Step by Step

Anyone considering a telehealth peptide program usually has the same question before anything else: what actually happens after I click sign up. Not the marketing language, the mechanics. Who looks at my information, what decides whether I get anything, and what does the routine look like once it starts. The sequence below is the one Embody Sermorelin describes for its own program.

The intake is a questionnaire, not an appointment

The process starts with a short online health assessment. There's no in-person exam and no waiting room. Embody Sermorelin puts this step at around five minutes: a set of questions about health history, current medications, and goals, submitted through a web form.

This is the part people sometimes assume works differently. It isn't a chat with a stranger or a quiz that guarantees an outcome. It's an intake form, the same kind of information a doctor's office would ask for on a first visit, just collected before any conversation happens instead of during one.

A licensed provider decides before anything ships

The assessment goes to a licensed provider for review. This step is the actual decision point in the process, and it happens before any medication is filled or shipped. The provider looks at what was submitted and determines whether a prescription is appropriate for that person.

This matters because it means the sign-up form isn't a purchase in the ordinary sense. It's a request for a clinical review, and the review can result in no prescription at all. Embody Sermorelin structures its refund policy around this: if the request isn't approved, the customer is refunded in full. That's a billing policy tied to the approval decision, not a claim about how well the medication works for anyone who is approved.

One more point worth stating clearly: sermorelin, the peptide involved here, doesn't currently have an FDA-approved version on the market. The last approved product, GEREF, left the market in 2009 when its manufacturer discontinued it, and the FDA later confirmed that withdrawal wasn't for safety or effectiveness reasons. What's available today is compounded by licensed pharmacies rather than manufactured under an approved drug application. That distinction is worth knowing before reading further into how the medication gets to your door.

The pharmacy step

Once approved, the prescription goes to a pharmacy to be filled. For an injectable like sermorelin, that means a sterile compounded preparation, which is why the pharmacy side of this process operates under real standards rather than none at all. USP General Chapter <797> sets the requirements sterile compounding must meet: trained personnel, controlled facilities, environmental monitoring, and testing of the finished preparation, aimed at keeping the product sterile and minimizing particulate matter. It's a quality standard for the compounding step specifically, not a description of the telehealth process around it, but it's the standard the pharmacy fill has to meet before your medication ships.

Details on how one specific program handles this, including its stated flat monthly price and its no-insurance structure, are laid out on the Embody Sermorelin program page. Embody Sermorelin describes its fill happening through a U.S. partner pharmacy operating in FDA-registered facilities. FDA's own framework for compounding places substances like sermorelin acetate on a bulk-drug-substance list it evaluates for outsourcing-facility use, which is consistent with treating it as a compounded product rather than a component of an approved drug currently sold under that approval.

What the ongoing routine looks like

After the first shipment, the routine is largely self-managed. Embody Sermorelin describes a once-weekly injection, so the recurring step happens at home rather than in a clinic, and there's no requirement to return for repeat in-person visits to continue.

Ongoing contact with a provider generally happens through a messaging system rather than scheduled appointments. If something changes or a question comes up, that conversation happens through messages rather than a phone tree or a booked slot. For anyone weighing whether a program like this fits their schedule, that's often the detail that matters most: the ongoing commitment is a weekly injection and access to messaging, not a series of visits.

Cancellation is structured the same simple way: Embody Sermorelin states no fixed contract and cancel any time. Combined with the approval-based refund, the billing side of the program rests on two decision points, whether you're approved and whether you want to continue, rather than on any guarantee of results.

This is also where the cost picture becomes concrete rather than theoretical. Embody Sermorelin states a flat $99 per month, with the price locked and no insurance involved, instead of a menu of visit charges and refill costs billed separately. Whether that structure fits a given budget is a separate question from whether the medication is right for someone, and it's the kind of detail worth confirming on the program's own page before signing up rather than assuming from a general description.

For a broader look at what to expect across a peptide program from sign-up through the ongoing routine, see the complete peptide guide collection.

What this process doesn't include

It's worth being direct about what isn't part of this sequence. There's no in-person physical exam, and the program doesn't describe one. There's no guarantee of approval either, which is exactly why the refund policy exists. Nothing about the process, including the Embody Sermorelin program page, amounts to a promise about what the medication will or won't do for a given person. That's a clinical question for the licensed provider reviewing the individual case, not something a sign-up form can answer in advance.

Sources

• USP General Chapter <797>, Pharmaceutical Compounding, Sterile Preparations. https://www.usp.org/compounding/general-chapter-797, standard for sterile compounded preparations across pharmacy settings; defines personnel, facility, monitoring, and testing requirements for the pharmacy-fill step; a quality standard, not a description of telehealth intake or messaging.
• Federal Register, "Determination That GEREF (Sermorelin Acetate) Injection... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness" (2013). https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams, administrative record confirming the last FDA-approved sermorelin product left the market in 2009 for business reasons, not safety or effectiveness; basis for stating any sermorelin dispensed today is compounded; administrative, not clinical, evidence.
• FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B. https://www.fda.gov/media/94164/download, regulatory categorization listing sermorelin acetate among bulk drug substances FDA evaluates for compounding; defines the pharmacy-fill step referenced above; describes a regulatory category, not any single pharmacy's practices.

Educational content only. Not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, changing, or stopping any medication, peptide, or supplement.